Synonym
UR-8880; UR8880; UR8880; Cimicoxib; trade name: Cimalgex.
IUPAC/Chemical Name
4-[4-Chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl]benzenesulfonamide
InChi Key
KYXDNECMRLFQMZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H13ClFN3O3S/c1-24-14-7-2-10(8-13(14)18)15-16(17)20-9-21(15)11-3-5-12(6-4-11)25(19,22)23/h2-9H,1H3,(H2,19,22,23)
SMILES Code
O=S(C1=CC=C(N2C(C3=CC=C(OC)C(F)=C3)=C(Cl)N=C2)C=C1)(N)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Cimicoxib that inhibits COX-2 selectively over COX-1 (IC50s = 0.005 and 3.3 μM, respectively).
In vivo activity:
Quinidine, a specific CYP2D15 inhibitor, is the most potent inhibitor of the metabolism of cimicoxib in canine and feline microsomes. Therefore, CYP2D15 is the main enzyme involved in the in vitro metabolism of cimicoxib in both species, among those tested. To a lower extent, CYP3A12 is also involved in the in vitro metabolism of cimicoxib. Quinidine inhibition of the metabolism of cimicoxib was about 30 times more potent in feline microsomes than in canine microsomes. As these results were obtained by competitive inhibition, the affinity of cimicoxib towards the enzyme was about 30 times lower in feline microsomes compared to canine microsomes. This activity difference may contribute to the slower in vivo elimination of cimicoxib in cats.
Reference: Vet J. 2021 Apr;270:105625. https://pubmed.ncbi.nlm.nih.gov/33641805/
Preparing Stock Solutions
The following data is based on the
product
molecular weight
381.81
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
In vivo protocol:
1. Schneider M, Dron F, Cuinet E, Woehrlé F. Comparative pharmacokinetic profile of cimicoxib in dogs and cats after IV administration. Vet J. 2021 Apr;270:105625. doi: 10.1016/j.tvjl.2021.105625. Epub 2021 Feb 1. PMID: 33641805.
2. Di Salvo A, Giorgi M, Lee HK, Vercelli C, Rueca F, Marinucci MT, Rocca GD. Plasma profile of cimicoxib in sheep after oral administration at two different rates. Pol J Vet Sci. 2017 Sep 26;20(3):535-538. doi: 10.1515/pjvs-2017-0065. PMID: 29166275.
1: Schneider M, Kuchta A, Dron F, Woehrlé F. Disposition of cimicoxib in plasma and milk of whelping bitches and in their puppies. BMC Vet Res. 2015 Jul 31;11:178. doi: 10.1186/s12917-015-0496-4. PubMed PMID: 26228538; PubMed Central PMCID: PMC4521454.
2: Kropf J, Bennett RC, Self G, Monticelli P, Huuskonen V. Efficacy and safety of cimicoxib in the control of perioperative pain in dogs: a critique. J Small Anim Pract. 2014 Dec;55(12):652-3. doi: 10.1111/jsap.12302_1. PubMed PMID: 25470417.
3: Kim TW, Della Rocca G, Di Salvo A, Ryschanova R, Sgorbini M, Giorgi M. Evaluation of pharmacokinetic and pharmacodynamic properties of cimicoxib in fasted and fed horses. N Z Vet J. 2015 Mar;63(2):92-7. doi: 10.1080/00480169.2014.950355. Epub 2015 Jan 27. PubMed PMID: 25075617.
4: Kim TW, Lebkowska-Wieruszewska B, Owen H, Yun HI, Kowalski CJ, Giorgi M. Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs. Vet J. 2014 Apr;200(1):77-81. doi: 10.1016/j.tvjl.2013.12.020. Epub 2013 Dec 31. PubMed PMID: 24461644.
5: Jeunesse EC, Schneider M, Woehrle F, Faucher M, Lefebvre HP, Toutain PL. Pharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dog. BMC Vet Res. 2013 Dec 11;9:250. doi: 10.1186/1746-6148-9-250. PubMed PMID: 24330630; PubMed Central PMCID: PMC3892053.
6: Grandemange E, Fournel S, Woehrlé F. Efficacy and safety of cimicoxib in the control of perioperative pain in dogs. J Small Anim Pract. 2013 Jun;54(6):304-12. doi: 10.1111/jsap.12082. PubMed PMID: 23710692; PubMed Central PMCID: PMC3743348.
7: Giorgi M, Kim TW, Saba A, Rouini MR, Yun H, Ryschanova R, Owen H. Detection and quantification of cimicoxib, a novel COX-2 inhibitor, in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. J Pharm Biomed Anal. 2013 Sep;83:28-33. doi: 10.1016/j.jpba.2013.04.024. Epub 2013 Apr 25. PubMed PMID: 23685411.
8: Almansa C, Bartrolí J, Belloc J, Cavalcanti FL, Ferrando R, Gómez LA, Ramis I, Carceller E, Merlos M, García-Rafanell J. New water-soluble sulfonylphosphoramidic acid derivatives of the COX-2 selective inhibitor cimicoxib. A novel approach to sulfonamide prodrugs. J Med Chem. 2004 Oct 21;47(22):5579-82. PubMed PMID: 15481993.
